|Summary sheet: MPT|
|Common names||MPT, Methylpropyltryptamine|
|Routes of Administration|
N-Methyl-N-propyltryptamine (abbreviated MPT; also known as Methylpropyltryptamine) is a synthetic psychedelic of the tryptamine class that has reported to display powerful hallucinogenic and sometimes entactogenic effects. It is structurally analogous to N,N-dimethyltryptamine (DMT) and various base psychedelic tryptamines by which one can have a "breakthrough" experience such as MET, EPT, and DPT.
While little is known aboout the pharmacology of this substance, early reports indicate it shares that vaporizing or freebasing the compounds shares most of the core components of the DMT experience, just with its own stylistic pharmacodynamic and kinetic variations.
MPT is extremely uncommon and has little history of human usage. It has never been documented as being sold on the street and is instead primarily acquired through the use of research chemical vendors and outfits who specialize in the sale of exotic psychoactive chemicals.
- 1 Chemistry
- 2 Pharmacology
- 3 Subjective effects
- 4 Toxicity and harm potential
- 5 Legal issues
- 6 See also
- 7 External links
- 8 References
Due to the lack of research regarding the substance, all discussion regarding the pharmacology of it is purely based on its structure and subjective effect similarities to other tryptamine psychedelics such as psilocin and DMT. With this in mind, MPT is thought to act as an 5-HT2A partial agonist.
However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.
|This subjective effects section is a stub.|
As such, it is still in progress and may contain incomplete or wrong information.
You can help by expanding or correcting it.
Disclaimer: The effects listed below are cited from the subjective effect index, which is based on anecdotal reports and the personal experiences of PsychonautWiki contributors. As a result, they should be treated with a healthy degree of skepticism. It is worth noting that these effects will rarely (if ever) occur all at once, although higher doses will increase the chances of inducing a full range of effects. Likewise, adverse effects become much more likely on higher doses and may include serious injury or death.
- Drifting (melting, breathing, morphing and flowing)
- Colour shifting
- Depth perception distortions
- Perspective distortions
- Symmetrical texture repetition
- After images
- Brightness alteration
There are currently no anecdotal reports which describe the effects of this compound within our experience index. Additional experience reports can be found here:
Toxicity and harm potential
The toxicity and long-term health effects of recreational MPT use do not appear to have been studied in any scientific context and the exact toxic dose is unknown. This is because MPT is a research chemical with very little history of human use. Anecdotal evidence from people within the psychonaut community who have tried MPT suggests that there are no negative health effects attributed to simply trying the drug by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.
It is strongly recommended that one uses harm reduction practices when using this drug.
Tolerance and addiction potential
MPT is not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating.
Tolerance to the effects of MPT is built almost immediately after ingestion. After that, it takes about 3 days for the tolerance to be reduced to half and 7 days to be back at baseline (in the absence of further consumption). MPT presents cross-tolerance with all psychedelics, meaning that after the consumption of MPT all psychedelics will have a reduced effect.
Although many drugs are safe on their own, they can become dangerous and even life-threatening when combined with other substances. The list below contains some common potentially dangerous combinations, but may not include all of them. Certain combinations may be harmless in low doses of each but still increase the potential risk of death. Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.
- Tramadol - Tramadol lowers seizure threshold and psychedelics may cause occasional seizures.
- Stimulants - Stimulants may provoke anxiety or thought loops.
This legality section is a stub.
As such, it may contain incomplete or wrong information. You can help by expanding it.
- Germany: MPT is controlled under the NpSG (New Psychoactive Substances Act) as of July 18, 2019. Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.
- New Zealand: MPT is an analogue of DMT, so is a Class C controlled drug in New Zealand.
- United Kingdom: MPT is a Class A drug in the United Kingdom as a result of the tryptamine catch-all clause.
- United States: MPT is unscheduled in the United States. It may be considered an analogue of DET, a Schedule I drug under the Controlled Substances Act. As such, the sale for human consumption or the use for illicit non-medical or industrial intents and purposes could be prosecuted as crimes under the Federal Analogue Act.
- Dose-independent occurrence of seizure with tramadol - Springer | http://link.springer.com/article/10.1007/BF03161089#/page-2
- "Verordnung zur Änderung der Anlage des Neue-psychoaktive-Stoffe-Gesetzes und von Anlagen des Betäubungsmittelgesetzes" (PDF) (in German). Bundesanzeiger Verlag. Retrieved December 10, 2019.
- "Anlage NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 10, 2019.
- "§ 4 NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 10, 2019.
- Misuse of Drugs Act 1971 (Legislation.gov.uk) |http://www.legislation.gov.uk/ukpga/1971/38/schedule/2/part/I#reference-M_F_c7632653-ddad-4420-f307-e3da1e36d30e